Bristol Tax Reporting (Correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers.In a story on Bristol's latest earnings restatement, "The Pink Sheet" DAILY incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" DAILY, March 15, 2004)
You may also be interested in...
Bristol Re-Restates; Income Taxes, "Grants" May Be Ongoing Issues
The company adjusts reported 2003 revenues by about $200 mil. Although impact of Bristol's second restatement is smaller than the first, tax issues and treatment of "grants" as advertising expenses could hint at deeper issues.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.